Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.21%
1,091.51
-2.30
-0.21%
—1,093.811,096.521,100.221,091.51——
SIXC
Communications
SIXC
Communications
SIXC
+0.22%
610.11
+1.34
+0.22%
—608.77608.77612.97608.77——
SIXE
Energy
SIXE
Energy
SIXE
-1.34%
1,237.98
-16.83
-1.34%
—1,254.811,253.011,253.871,226.33——
SIXI
Industrials
SIXI
Industrials
SIXI
-0.93%
1,744.71
-16.40
-0.93%
—1,761.111,764.271,766.881,744.71——
SIXM
Financials
SIXM
Financials
SIXM
-0.37%
640.18
-2.40
-0.37%
—642.58644.87648.48640.18——
SIXR
Staples
SIXR
Staples
SIXR
-0.18%
849.58
-1.55
-0.18%
—851.13855.66858.75845.56——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0.23%
217.48
-0.50
-0.23%
—217.98217.98218.65216.88——
SIXT
Technology
SIXT
Technology
SIXT
+1.52%
3,260.69
+48.86
+1.52%
—3,211.833,227.213,268.383,226.55——
SIXU
Utilities
SIXU
Utilities
SIXU
-0.69%
942.45
-6.53
-0.69%
—948.98948.58957.83941.97——
SIXV
Health care
SIXV
Health care
SIXV
-0.52%
1,466.80
-7.72
-0.52%
—1,474.521,479.031,481.041,466.80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0.22%
2,397.50
+5.38
+0.22%
—2,392.122,396.952,421.222,382.32——
ADAPY:OTCMKTS
Adaptimmune Therapeutics PLC - ADR
$0.0036
-64.00%
(-0.0064) 1D
May 1, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ADAPY...
Open
$0.00
High
$0.02
Low
$0.00
Mkt. cap
954.19K
Volume
64.61K
52-wk high
$0.02
52-wk low
$0.00
EPS
-$0.66
Beta
1.89
Shares outstanding
265.05M
No. of employees
506
News stories
From sources across the web
Profile
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park. In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer. Tecelra is the first T cell therapy to be approved for use against a solid tumor. In January 2025, the FDA granted breakthrough therapy designation to Adaptimmune's Letetresgene Autoleucel for Treatment of Myxoid/Round Cell Liposarcoma. In July 2025, Adaptimmune announced their entry into a Definitive Agreement for Sale of Tecelra, lete-cel, and the pre-clinical uza-cel to US WorldMeds for $55M. Wikipedia
About Adaptimmune Therapeutics PLC - ADR
CEOAdrian Rawcliffe
Employees506
Founded2008
Headquarters-
SectorBiotechnology
Websiteadaptimmune.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Revenue
40.90M
3.22M
7.28M
13.68M
Cost of goods sold
34.30M
39.17M
29.74M
25.48M
Cost of revenue
34.30M
39.17M
29.74M
25.48M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
21.28M
28.56M
21.62M
18.48M
Operating expense
21.28M
28.56M
21.62M
18.48M
Total operating expenses
55.58M
67.74M
51.36M
43.96M
Operating income
-14.68M
-64.51M
-44.07M
-30.29M
Other non operating income
-
-
-
-
EBT including unusual items
-16.79M
-72.52M
-47.01M
-29.73M
EBT excluding unusual items
-16.79M
-63.52M
-45.35M
-29.73M
Income tax expense
831.00K
1.69M
575.00K
612.00K
Effective tax rate
-4.95%
-2.33%
-1.22%
-2.06%
Other operating expenses
-
-
-
-
Net income
-17.62M
-74.22M
-47.58M
-30.34M
Net profit margin
-43.07%
-2,303.38%
-653.18%
-221.83%
Earnings per share
-0.01
-0.24
-0.18
-0.12
Interest and investment income
2.10M
1.78M
910.00K
233.00K
Interest expense
-1.11M
-1.71M
-1.88M
-962.00K
Net interest expenses
987.00K
66.00K
-971.00K
-729.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-11.86M
-61.68M
-41.60M
-27.78M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer